结直肠癌中林奇综合征筛查的成本效益:通用胚系检测与序贯筛查比较
该研究基于前瞻性林奇综合征数据库、美国国家癌症研究所监测流行病学与最终结果项目及干预前后队列数据,构建结直肠癌先证者终生马尔可夫模型,比较当前标准诊疗、优化标准诊疗和 upfront 胚系检测三种策略的成本效益。结果显示当前临床实践不具成本效益,优化干预使林奇综合征检测率达到75%以上或无法达到该水平时采用 upfront 胚系检测均具成本效益。
要点
- 当前标准诊疗在10000次蒙特卡洛迭代中仅0.0%被偏好,属不具成本效益。
- 优化标准诊疗相比当前标准诊疗的增量成本效益比为每质量调整生命年34500美元(95%可信区间28400至44200美元)。
- upfront 胚系检测相比当前标准诊疗的增量成本效益比为每质量调整生命年70300美元(95%可信区间54600至92500美元)。
核心结论
- 当前临床实践不具成本效益;前瞻性干预使林奇综合征检测率大幅提高至超过75%阈值,或若无法达到该水平则采用 upfront 胚系检测,均为可改善质量调整预期寿命且具成本效益的干预措施。
研究设计与样本
- 基于前瞻性林奇综合征数据库、美国国家癌症研究所监测流行病学与最终结果项目及干预前后队列研究数据,构建结直肠癌先证者终生马尔可夫队列,从美国卫生系统视角比较三种策略:当前标准诊疗、优化标准诊疗和 upfront 胚系检测,主要结局为每质量调整生命年的增量成本效益比。
主要发现
- 三种策略分别累积11.97、11.98和11.99个贴现质量调整生命年,贴现成本分别为100610美元、100980美元和102290美元。
- 效率前沿上的成对增量成本效益比分别为每质量调整生命年34500美元(95%可信区间28400至44200美元)和每质量调整生命年98500美元(95%可信区间73700至216000美元)。
- upfront 胚系检测相比当前标准诊疗的增量成本效益比为每质量调整生命年70300美元(95%可信区间54600至92500美元)。
- 当前标准诊疗在10000次蒙特卡洛迭代中仅0.0%被偏好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Testing all colorectal cancers (CRCs) for mismatch repair status to evaluate for Lynch syndrome (LS) has been recommended for years. Owing to attrition in the multistep diagnostic testing pathway, most qualifying patients still do not receive genetic testing for LS. This leads to missed diagnoses and preventable cancer incidence. To tackle this, we previously reported a systems approach that resulted in a dramatic increase in the identification of patients with LS. We aim to evaluate the cost-effectiveness of this intervention compared with both real-world pre-intervention experience and with upfront germline testing of all CRC probands. METHODS: We employed data from the Prospective Lynch Syndrome Database, the National Cancer Institute Surveillance, Epidemiology, and End Results program, and pre-/post-intervention cohort studies to build lifetime Markov cohorts of CRC probands, testing 3 strategies: (1) current standard-of-care; (2) optimized standard-of-care; and (3) upfront germline testing. The primary outcome was the incremental cost-effectiveness ratio (ICER) in $ per quality-adjusted life-year (QALY) from the United States health system perspective. RESULTS: Strategies #1 to #3 accrued 11.97, 11.98, and 11.99 discounted QALYs at discounted costs of $100,610, $100,980, and $102,290, respectively. The pairwise ICERs on the frontier were $34,500/QALY (95% credible interval [CI], $28,400-$44,200) and $98,500/QALY (95% CI, $73,700-$216,000), respectively. The cost-effectiveness of #3 vs #1 was $70,300/QALY (95% CI, $54,600-$92,500). Current standard-of-care was favored in 0.0% of 10,000 Monte Carlo iterations. CONCLUSIONS: Current clinical practice is cost-ineffective. Prospective intervention to dramatically increase LS testing (ie, to reach a threshold of >75%) or, if this level cannot be reached, upfront germline testing are cost-effective interventions that improve quality-adjusted life expectancy.
引用
- Ito S, Xicola RM, Sra M, et al. Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer: Universal Germline vs Sequential Screening. Clin Gastroenterol Hepatol. 2025. PMID: 40315972. doi:10.1016/j.cgh.2025.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。